Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome 20S subunit beta 6 (PSMB6) is a critical component of the 20S core proteasome, a cylindrical, multi-subunit protease complex present in all eukaryotic cells responsible for ATP- and ubiquitin-dependent degradation of intracellular proteins. PSMB6 is one of seven beta subunits forming the two inner rings of the 20S core, and is associated with caspase-like (peptidyl-glutamyl hydrolase) activity, cleaving after acidic residues. The proteasome is essential for cell homeostasis, cell cycle regulation, antigen processing, and removal of misfolded or damaged proteins. Dysregulation of proteasome activity is implicated in cancer, neurodegenerative diseases, and other disorders, and 20S subunits including PSMB6 are targets for approved anticancer drugs known as proteasome inhibitors.
Proteasome inhibitors (e.g., bortezomib, carfilzomib) bind and inhibit the proteolytic activity (caspase-like/caspase-like, chymotrypsin-like, trypsin-like) of the 20S core, blocking substrate protein degradation and leading to apoptosis in rapidly dividing or stressed cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome 20S subunit beta 6 (PSMB6).